Evidence map›Paper›PMID 27291652›Full record

Trial reportThe Journal of urology2016

Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States.

Samir S Taneja, James Bennett, Jonathan Coleman, Robert Grubb, Gerald Andriole, Robert E Reiter, Leonard Marks, Abdel-Rahmene Azzouzi, Mark Emberton

Registry-linked trialOpen access · greenAbstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00946881 (A Prospective, Multicenter Phase I/II Safety and Tolerability Study of Unilateral Vascular-Targeted Photodynamic Therapy Using WST11 in Patients With Localized Prostate Cancer), which is not on this map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00946881 phase1 / phase2completednot on this map

A Prospective, Multicenter Phase I/II Safety and Tolerability Study of Unilateral Vascular-Targeted Photodynamic Therapy Using WST11 in Patients With Localized Prostate Cancer

TypeinterventionalSponsorSteba Biotech S.A.Ran2009 to 2012Enrolled30ConditionsProstate CancerArmsWST 11 -mediated -VTP
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Review
  8. Comparison of mpMRI andDiagnostics (Basel, Switzerland) · 2025
    Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. A Canadian center's experience on whole-gland salvage therapy for radio-recurrent prostate cancer with various modalities.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2023
    Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 3 countries.

Samir S TanejaDivision of Urologic Oncology, Department of Urology, New York University Langone Medical Center, New York, New York. Electronic address: samir.taneja@nyumc.org.
James BennettDepartment of Urology, Emory University Hospital Midtown/Midtown Urology, Atlanta, Georgia.
Jonathan ColemanDepartment of Urology, Memorial Sloan Kettering Cancer Center, New York, New York.
Robert GrubbDepartment of Urology, Washington University School of Medicine, St. Louis, Missouri.
Gerald AndrioleDepartment of Urology, Washington University School of Medicine, St. Louis, Missouri.
Robert E ReiterDepartment of Urology, University of California at Los Angeles School of Medicine, Los Angeles, California.
Leonard MarksDepartment of Urology, University of California at Los Angeles School of Medicine, Los Angeles, California.
Abdel-Rahmene AzzouziDepartment of Urology, Centre Hospitalier Universitaire d'Angers, Angers, France.
Mark EmbertonDivision of Surgery and Interventional Science, University College of London, London, United Kingdom.
University of California, Los Angeles · USWashington University in St. Louis · USCentre Hospitalier Universitaire d'Angers · FREmory University Hospital Midtown · USMemorial Sloan Kettering Cancer Center · USNYU Langone Health · USUniversity College London · GB

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Medical Research Council MR/M009092/1NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

purposeVascular targeted photodynamic therapy with WST11 (TOOKAD® Soluble) is a form of tissue ablation that may be used therapeutically for localized prostate cancer. To study dosing parameters and associated treatment effects we performed a prospective, multicenter, phase I/II trial of WST11 vascular targeted photodynamic therapy of prostate cancer. MATERIALS AND

methodsA total of 30 men with unilateral, low volume, Gleason 3 + 3 prostate cancer were enrolled at 5 centers after local institutional review board approval. Light energy, fiber number and WST11 dose were escalated to identify optimal dosing parameters for vascular targeted photodynamic therapy hemi-ablation. Men were treated with photodynamic therapy and evaluated by posttreatment magnetic resonance imaging and biopsy. Prostate specific antigen, light dose index (defined as fiber length/desired treatment volume), toxicity and quality of life parameters were recorded.

resultsAfter dose escalation 21 men received optimized dosing of 4 mg/kg WST11 at 200 J energy. On posttreatment biopsy residual prostate cancer was found in the treated lobe in 10 men, the untreated lobe in 4 and both lobes in 1. At a light dose index of 1 or greater with optimal dosing in 15 men 73.3% had a negative biopsy in the treated lobe. Six men undergoing retreatment with the optimal dose and a light dose index of 1 or greater had a negative posttreatment biopsy. Minimal effects were observed on urinary and sexual function, and overall quality of life.

conclusionsHemi-ablation of the prostate with WST11 vascular targeted photodynamic therapy was well tolerated and resulted in a negative biopsy in the treated lobe in the majority of men. Dosing parameters and the light dose index appear related to tissue response as determined by magnetic resonance imaging and biopsy. These parameters may serve as the basis for further prospective studies.

Indexed as

Quality of LifeAblation TechniquesAgedBacteriochlorophyllsBiopsyHumansMagnetic Resonance ImagingMaleMiddle AgedNeoplasm GradingPhotochemotherapyProspective StudiesProstate-Specific AntigenProstatic NeoplasmsTreatment OutcomeUnited StatesBacteriochlorophyllspadeliporfinProstate-Specific Antigenablation techniqueslaser therapyphotochemotherapyprostatic neoplasmsWST11 compound

Identifiers

PMID27291652
PMCPMC5483996
OpenAlexW2409121032

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.